Wanbury Ltd

Wanbury Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Wanbury Ltd

₹ 255 -0.31%
08 Aug 4:01 p.m.
wanbury.com BSE: 524212 NSE: WANBURY
About

Incorporated in 1988, Wanbury Ltd is in the business of pharmaceutical and related activities, including research[1]

Key Points

Business Overview:[1]
WL is a pharmaceutical company with a presence in the API global market and domestic branded Formulation. It’s majorly into Active Pharmaceutical Ingredient (API) Sales & Marketing in over 50 countries and Pan-India
Formulation presence

Website BSE NSE - BE
  • Market Cap ₹ 837 Cr.
  • Current Price ₹ 255
  • High / Low ₹ 330 / 154
  • Stock P/E 19.5
  • Book Value ₹ 18.1
  • Dividend Yield 0.00 %
  • ROCE 34.9 %
  • ROE 70.0 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has delivered good profit growth of 29.9% CAGR over last 5 years

Cons

  • Stock is trading at 14.1 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of 10.3% over past five years.
  • Tax rate seems low
  • Promoters have pledged or encumbered 76.7% of their holding.
  • Company's cost of borrowing seems high

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
117 124 126 133 146 144 146 139 131 161 133 172 163
120 118 119 119 133 127 124 121 120 141 120 142 139
Operating Profit -3 6 6 14 13 17 21 18 11 20 14 30 24
OPM % -3% 5% 5% 11% 9% 12% 15% 13% 8% 12% 10% 17% 15%
2 1 0 -3 1 1 1 26 1 2 1 2 0
Interest 3 4 7 8 6 8 8 7 8 10 10 9 8
Depreciation 3 3 3 3 3 3 3 3 3 3 3 3 4
Profit before tax -7 -1 -3 1 5 7 10 34 1 8 1 19 14
Tax % -3% 25% 8% -11% 6% -2% -0% 1% 0% 2% 5% -6% 1%
-7 -1 -3 1 5 7 10 34 1 8 1 20 13
EPS in Rs -2.21 -0.27 -1.00 0.31 1.43 2.25 3.14 10.27 0.32 2.45 0.37 6.18 4.10
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Sep 2014 18m Mar 2015 6m Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
661 250 420 432 370 391 367 392 511 485 557 600 630
637 228 387 414 438 375 344 374 475 459 484 523 542
Operating Profit 25 21 33 19 -68 16 23 18 36 26 73 76 88
OPM % 4% 9% 8% 4% -18% 4% 6% 5% 7% 5% 13% 13% 14%
-78 6 0 90 76 9 84 2 77 -3 26 3 5
Interest 48 19 32 36 31 40 33 23 21 21 29 37 37
Depreciation 23 5 9 10 10 10 10 10 11 12 13 13 14
Profit before tax -125 4 -7 62 -32 -25 65 -12 81 -10 56 30 42
Tax % 2% 28% 0% 1% -1% -1% 0% 2% -0% 1% 1% -3%
-128 3 -7 62 -32 -25 64 -13 81 -10 56 31 43
EPS in Rs -63.95 1.60 -3.58 26.71 -13.49 -10.48 25.79 -5.04 24.94 -3.18 17.09 9.32 13.10
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 9%
5 Years: 10%
3 Years: 5%
TTM: 12%
Compounded Profit Growth
10 Years: 25%
5 Years: 30%
3 Years: 75%
TTM: 60%
Stock Price CAGR
10 Years: 14%
5 Years: 46%
3 Years: 54%
1 Year: 28%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: 70%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Sep 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 20 20 20 23 24 24 25 25 33 33 33 33
Reserves -212 -214 -209 -176 -208 -233 -168 -181 -56 -66 -5 26
389 381 362 300 250 260 190 192 100 95 116 177
209 209 215 265 207 236 232 253 276 241 199 178
Total Liabilities 406 396 388 412 273 286 279 289 353 304 343 414
174 164 180 186 178 172 164 167 167 167 167 201
CWIP 13 19 14 10 10 9 14 11 2 2 3 5
Investments 0 0 0 0 0 0 0 0 0 0 0 0
219 213 193 216 84 105 101 111 183 135 174 208
Total Assets 406 396 388 412 273 286 279 289 353 304 343 414

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Sep 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
68 40 43 43 32 30 44 17 41 20 4 26
-6 -5 -20 -13 -1 -3 64 8 1 -9 -17 -51
-71 -30 -28 -27 -33 -27 -108 -17 -29 -32 15 26
Net Cash Flow -9 5 -5 3 -2 -0 -0 7 13 -21 2 1

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Sep 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 57 144 65 71 29 41 50 32 45 52 59 70
Inventory Days 42 103 69 63 27 36 25 41 60 26 43 47
Days Payable 113 301 172 260 174 209 253 221 218 179 196 172
Cash Conversion Cycle -14 -55 -38 -125 -118 -131 -177 -148 -113 -101 -94 -55
Working Capital Days -44 -140 -123 -185 -277 -254 -236 -251 -153 -152 -40 4
ROCE % 4% 12% 57% -1% 26% 31% 27% 46% 21% 61% 35%

Shareholding Pattern

Numbers in percentages

1 Recently
Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025
39.85% 39.84% 39.84% 39.84% 39.80% 39.79% 39.79% 39.79% 39.77% 39.76% 39.76% 39.63%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.18% 0.22% 1.02% 0.84% 1.55% 1.59%
60.16% 60.16% 60.16% 60.16% 60.19% 60.20% 60.02% 59.97% 59.21% 59.40% 58.68% 58.79%
No. of Shareholders 11,55511,88811,91111,74111,63411,61613,08714,40017,19917,99917,88917,894

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings